Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The total market for glucagon products for hypoglycaemia has been estimated to be worth around $2 billion worldwide. Lilly acquired rights to Baqsimi from Canadian biotech Locemia Solutions in ...

Retatrutide targets GIP and GLP-1 – the same as Lilly’s fast-growing diabetes therapy Mounjaro (tirzepatide) – but adds in activity against glucagon. That three-pronged attack helped ...

Eli Lilly (NYSE: LLY) has been in the limelight more frequently of late, with the success of its glucagon-like peptide-1 (GLP-1) drugs that have reinvigorated growth for one of the oldest ...